Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Synlogic Inc.
Headquarters: Cambridge, MA, United States of America
Website: http://synlogictx.com
Year Founded: 2014
Status: Public
Industry Sector: HealthTechnology
CEO: Mary Beth Dooley
Number Of Employees: 1
Enterprise Value: $-1,785,307
PE Ratio: -0.42
Exchange/Ticker 1: NASDAQ:SYBX
Exchange/Ticker 2: N/A
Latest Market Cap: $12,397,900
BioCentury | Dec 13, 2024
Product Development
Only the paranoid survive, and the CEO’s paradox, from Aoife Brennan
How CEOs are managing through uncertainty, and why ‘boring’ naked mAbs are the smart move in one field
BioCentury | Dec 5, 2024
Management Tracks
Várhelyi to lead health at EU
Plus updates from Nouscom, Eton, Healx, Medipost, Fairjourney, Italfarmaco and Cellino
BioCentury | Oct 4, 2024
Management Tracks
Resolution names Paul Sekhri chair
Plus: Dadswell leaving Illumina as general counsel and updates from Eliem, Codexis, Oculis, Illumina, Eupraxia and PharmaJet
BioCentury | Jun 26, 2024
Management Tracks
Arvinas, Frontier name new CFOs
Plus: Audrey Duval to lead corporate affairs at Sanofi, and updates from MOMA,
BioCentury | Feb 14, 2024
Product Development
Clinical report: Data from Gilead, KalVista, Takeda, Synlogic and AN2
What Gilead’s CD47 failure means for the class; KalVista to submit HAE program; Takeda advances narcolepsy therapy; and more
BioCentury | Aug 17, 2023
Discovery & Translation
Improved transgene insertion; plus Synlogic’s autoimmune probiotic and more
BioCentury’s roundup of translational innovations
BioCentury | Jan 4, 2023
Management Tracks
Ex-Checkmate CEO Bash to lead ZielBio
Plus: Allogene’s Amado joins Zai Lab, and updates from bluebird bio, Rejuvenate, Novadip and more
BioCentury | Nov 23, 2022
Data Byte
Phenylketonuria pipeline breaks into new modalities
New approaches go beyond small molecules and enzymes to bacteria, mRNA, protein and gene therapies
BioCentury | Sep 6, 2022
Regulation
Sept. 6 Quick Takes: FDA lifts clinical hold on Sarepta DMD trial
Plus Arsenal raises $220M and updates from Roche, Phoremost, Synlogic and more
BioCentury | Aug 31, 2022
Management Tracks
Biopharma is headed in the right direction on DEI. Now put the foot on the gas
Commitment to diversity, equity and inclusion is necessary but not sufficient. Balancing out the C-suite is the step change that’s needed
Items per page:
1 - 10 of 95